Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Type 1 interferons: A target for Immune-mediated inflammatory diseases (IMIDs)

Mathian A. et al, (2025), Revue du rhumatisme (edition francaise)

A cellular overview of immunometabolism in systemic lupus erythematosus

Psarras A. and Clarke A., (2023), Oxford open immunology, 4

Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus.

Psarras A. and Vital EM., (2022), N engl j med, 387, 1528 - 1529

Emerging concepts of type I interferons in SLE pathogenesis and therapy

Psarras A. et al, (2022), Nature reviews rheumatology

Keratinocytes: From passive targets to active mediators of systemic autoimmunity

Psarras A. and Vital EM., (2022), Science translational medicine, 14

A critical view on cardiovascular risk in systemic sclerosis.

Psarras A. et al, (2017), Rheumatol int, 37, 85 - 95

Giant cell arteritis and systemic sclerosis: a rare overlap syndrome

Psarras A. et al, (2014), Rheumatology reports, 6

Load More